Sources_sought.pdf

SOURCES SOUGHT

The Government is conducting market research to identify potential sources that possess the expertise, capabilities, and experience to meet the requirements of the follow-on contract for Expert Second Opinion for Pathology Consultation Services for the Wright-Patterson Medical Center at Wright-Patterson AFB, OH.

CAUTION: This Sources Sought is issued solely for information and planning purposes. In accordance with Part 10 of the Federal Acquisition Regulation, the U.S. Government is conducting market research. The intended purpose is to identify potential sources that may possess the expertise, capabilities, and experience to meet the Wright-Patterson AFB Medical Center’s requirements. It does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future. Further, AFLCMC is not at this time seeking proposals and will not accept unsolicited proposals. Responders are advised that the Government will not pay for any information or administrative costs incurred in response to this sources sought. Please be advised that all submissions become Government property and will not be returned. All costs associated with responding to this sources sought will be solely at the responding party’s expense. Not responding to this sources sought does not preclude participation in any future RFP, if issued. In accordance with Federal Acquisition Regulation 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. It is the responsibility of the interested parties to monitor this FedBizOps website for additional information pertaining to this sources sought notice.

INSTRUCTIONS:

1. The document below provides a description of the Expert Second Opinion for Pathology Consultation Services along with a Contractor Capability Survey, which affords an opportunity to provide your company’s capabilities.

2. If after reviewing these documents you desire to participate in the market research, please respond to the Contractor Capability Survey to document your company’s capabilities in meeting these requirements. Failure to provide a complete response may result in the Government being unable to adequately assess your capabilities. If you lack sufficient experience or capability in a particular area, please provide details explaining how you would overcome the lack of experience/capabilities in order to perform that portion of the requirement (i.e., teaming, subcontracting, etc.)

3. Both large and small businesses are encouraged to participate in this Market Research.

Joint ventures or teaming arrangements are encouraged.

4. Questions relative to this market survey should be addressed via email to Rebecca Houghton (AFLCMC/PZIOAB), rebecca.houghton@us.af.mil. Responses to questions from interested parties will be promptly answered and posted on this FedBizOps website, unless some release of proprietary information is involved or the answer addresses a question peculiar to a company or that company’s response. Verbal questions will NOT be accepted.

5. If your company is interested, e-mail your responses to rebecca.houghton@us.af.mil. All responses must be received no later than 20 January 2017 EST 4:00 pm.

mailto:rebecca.houghton@us.af.mil mailto:rebecca.houghton@us.af.mil

6. The response to Part I. Business Information should be single spaced, 12 pt font. The response to Part II. Capabilities should be limited to no more than 20 pages (8.5x11 inches), single spaced, 12 pt font. In addition, identify a representative to support further Government inquiries and requests for clarification of the information provided, if needed.

Respondents should indicate which portions of their response are proprietary and should mark them accordingly. The Air Force will handle proprietary items in accordance with FAR 2.101 and 3.104.

Requirements:

Expert Second Opinion for Pathology Consultation Services, Ancillary Diagnostic Immunohistochemical (IHC) Testing. Prognostic and Therapeutic Testing, and Electron Microscopy(EM), Direct Immunofluorescence , and Microscopic exam of Brain/Nerve, Renal, Muscle, and Hematopathology for Anatomic Pathology.

Please provide a list of in-house services for:

• Expertise for second opinion consultation services

• Immunohistochemical diagnostic (IHC) stains

• Molecular Diagnostic, Prognostic and Therapeutic laboratory tests currently available

• A complete list of comprehensive services covering Brain/Nerve, Renal, Muscle tissue, Hematopoetic, and Direct Immunofluorescence (skin)

Specific tests sought: Please note, Contractor may provide 1 set or all sets of tests, but all sets of tests must be filled to satisfy the requirements:

a. Subspecialties of diagnostic pathology: Soft Tissue, Bone, Hematopathology, Gynecologic Pathology, Dermatopathology , Gastrointestinal Pathology, Urologic Pathology, Head and Neck Pathology, Cytopathology, Endocrine Pathology, Pulmonary Pathology, Renal Biopsy, Breast Pathology, and Neuropathology.

b. Ancillary testing: Immunohistochemical Diagnostic Antibody stains: A-AT, ACTH, Actin, Adeno,AE1, AE1/AE3, AE3, AFP,ALK,ALK-1,AMYLOID A, ANNEXIN A1, B72.3, BCL-1(Cyclin D1), BCL-2, BCL-6, B-CATENIN, BER-EP4, BOB.1,C4d, CA19.9,CA125(OC125), CAIX, CALCITONIN, CALDESMON, CALPONIN, CALRETININ, CAM 5.2, CAM5.2/AE1, CD1a, CD2, CD3, CD4, CD5 (4C7), CD7, CD8, CD10, CD15, CD20, CD21, CD22, CD23, CD25, CD30, CD31, CD33, CD34, CD35, CD43, CD45, CD45RO, CD56, CD57, CD61, CD68, CD71, CD79a, CD99, CD117, CD123, CD138, CD163, CDX2, CEA (M), CEA(P), CHROMOGRANIN, CHROMOTRYPSIN, CK5, CK5.6, CK7, CK14, CK17, CK19, CK20, CK903, c-MET, CMV, COLL IV, D2-40, DBA44, DESMIN, DOG1, EBV, E-CADHERIN, EGFR, EMA, ER, FACTOR V111, FACTOR V111a, FLI-1, FSH, GALECTIN-3, GASTRIN, GCDFP-15, GFAP, GH, GLUCAGON, GLYPICAN-3, GPH-A, GRANZYME B, UNCLASSIFIED//FOUO

Sources Sought

HEMAGLOBIN A, HP B CORE, HEP B SURF, HBME-1, HBP (H. pylori), HCAg, HCG, HEP PAR 1, HER2, HHV8, HLA-DR, HMB-45, HPAP, HPL,HSV, IgA, IgD, IgG, IgG4, IgM, INHIBIN, INSULIN,Ki-67, LH, LIPASE, MAMMAGLOBIN, MART-1, M-CELL

TYRPTASE, MELAN-A, MITF, MLH-1, MOC31, MPO, MSH-2, MSH-6, MUC-1, MUC-2,

MUM1, MURA, MYOD1, MYOGENIN, NAPSIN-A, NEU-N, NEUROFILAMENT, NKI,

NPM, NSE, OCT-2, OCT3/4, P16, P504S, P53, P57, P63, P120, Pan Melanoma, PAX2, PAX5, PAX8, PC, PD1,PIN-4, PLAP, PML, PMS- 2, PNRA (RCC), PR, PROLACTIN, PTS

(Prostate Triple Stain), PSA, PTH, RB, S100, SEROTONIN, SMA, SMM, SOMA, SP-A, SYNAPTOPHYSIN, TAU, TCL-1, TDT, THROMBOMODULIN, THYROGLOBULIN, TIA-1, TOXO, TRAP, TRYPSIN, TS, TSH, TTF-1,UBIQUITIN, UROPLAKIN III, VIMENTIN, VZV, WT-1 C-terminus, WT-1 N-terminus, ZAP-70.

c. Additional Diagnostic, Prognostic and Therapeutic testing: ER, PR, HER2 by IHC and FISH, Ki-67, p53, EGFR, DNA plyoidy/S-Phase, E-Cadherin, Circulating Tumor Cells, HERmark, Tamoxifen, BRAF (PCR), KRAS(PCR), NRAS(PCR), MSI(PCR), EGFR(FISH), TS, DNA, EGFR(IHC), Circulating Tumor Cells, Lynch Syndrome (HNPCC), MLH1/MSH2/MSH6/PMS2 (IHC), MSI (PCR), ALK(FISH), ROS1 (FISH), RET (FISH), BRAF Mutation Analysis (cobas), c-Kit Mutation Analysis, PDGFRA Mutation Analysis(PCR), 1p19q deletions (FISH), MGMT Methylation, TP2A (FISH),DNA (Cell Cycle Analysis),PIK3CA(PCR),Lynch Syndrome, Microsatellite Instability(MSI) FFPE, NSCLC(FISH), REA(FISH)EGFR(PCR),EML4-ALK(PCR),PIK3CA(PCR),ALK 2p23 Rearrangement NSCLC (FISH), ERCC1 (IHC), VYSIS (FISH), Chomosome Analysis (Lymphnode/Solid Tumor), Sarcoma Mutation Analysis(pediatric PCR),Melanoma (BRAF V600 Mutation), BRAF(Mutation Analysis), HPV Low and High Risk DNA (FISH),Flow Cytometry (Leukemia/Lymphoma Phenotyping), Flow Cytometry (ZAP-70 Analysis), Flow Cytometry (PNH Evaluation), Cytogenetics (Chromosome Analysis), Cytogenetics/FISH(Chromosome Analysis),AML1/ETO(PCR)quantitative, CBFB/MYH11 inv(16)(PCR) quantitative, CEBPA Mutation(PCR), FLT3 (PCR), NPM1 Mutation(PCR), PML/RARA quantitative(PCR), Wilms Tumor (WT1)mutation (PCR), IgVH Mutation Status, p53 Mutation Analysis, BCL2/JH t(14;18), BCR-ABL 1 Gene Rearrangement quantitative, ABL1 Kinase Domain mutation, ABL1 T3151 mutation in CML, JAK2 V617F, JAK2 V617, JAK2 exons 12,13, MPL analysis only, Lympocyte Clonality Panel (PCR), Qualitative B-Cell Gene Rearrangement, Qualitative T-Cell Gene Rearrangement, BCL1/JH T(11;14).

d. Specialized testing for Electron Microscopy(EM), Direct Immunofluorescence (skin) , and Microscopic exam of Brain/Nerve, Renal, Muscle, and Hematopathology Tissues.

Additionally, in-house ability to perform tests is required, a client services representative shall be provided to address questions, and a 2-day turnaround time is required.

CONTRACTOR CAPABILITY SURVEY

Part I. Business Information

Please provide the following business information for your company/institution and for any teaming or joint venture partners:

• Company/Institute Name:

• Address:

• Point of Contact:

• CAGE Code:

• Phone Number:

• E-mail Address:

• Web Page URL:

• Size of business pursuant to North American Industry Classification System (NAICS) Code:

Based on NAICS Code 621511, state whether your company is:

o Small Business (Yes / No) o Woman Owned Small Business (Yes / No) o Economically-Disadvantaged Women-Owned Small Business (Yes / No) o Small Disadvantaged Business (Yes / No) o 8(a) Certified (Yes / No) o HUBZone Certified (Yes / No) o Veteran Owned Small Business (Yes / No) o Service Disabled Veteran Small Business (Yes / No)

*All interested contractors must be registered in SAM in order to be eligible for award of Government contracts. The government reserves the right to consider a small business set-aside based upon responses hereto for any subsequent action.

• A statement as to whether your company is domestic or foreign owned (if foreign, please indicate the country of ownership).

ATTENTION Small business respondents interested in submitting a proposal as the prime contractor for this effort:

No set aside decision has been made; however, the Air Force is contemplating setting this acquisition aside for Small Businesses if there is sufficient demonstrated interest and capability. Note that a key factor in determining an acquisition to be a Small Business Set Aside is that two or more small businesses prime contractors must be capable of performing at least 50% of the entire scope of the service effort.

ATTENTION all potential respondents:

The acquisition strategy for this program has not been finalized. If this acquisition is not set aside for small business, it is anticipated that the contract may contain a small business utilization requirement.

Part II. Capability Survey Questions

1. Describe your company's capabilities and experience.

2. Describe your company's past experience on previous projects similar in complexity to this requirement. Include contract numbers, a brief description of the work performed, period of performance, and agency/organization supported.

3. Are there established market prices for our requirement? If you offer this product and/or service to both U.S. Government and commercial sources, is the same workforce used for both the U.S. Government and general public? Is our requirement offered to both under similar terms and conditions? Briefly describe any differences.

Part I. Business Information